The sialidase NEU3 promotes pulmonary fibrosis in mice

Darrell Pilling*, Kyle Sahlberg, Tejas R. Karhadkar, Wensheng Chen and Richard H. Gomer*

Abstract
Background: Sialic acid is often the distal sugar on glycoconjugates, and sialidases are enzymes that remove this sugar. In fibrotic lesions in human and mouse lungs, there is extensive desialylation of glycoconjugates, and upregulation of sialidases including the extracellular sialidase NEU3. In the bleomycin model of pulmonary fibrosis, mice lacking NEU3 (Neu3−/−) showed strongly attenuated bleomycin-induced weight loss, lung damage, inflammation, and fibrosis. This indicates that NEU3 is necessary for the full spectrum of bleomycin-induced pulmonary fibrosis.

Methods: To determine if NEU3 is sufficient to induce pulmonary fibrosis, recombinant murine NEU3 and a mutated inactive recombinant murine NEU3 protein were produced. Mice were given recombinant NEU3 proteins by oropharyngeal aspiration, either alone or 10 days after bleomycin challenge. Over the course of 21 days, mice were assessed for weight change, and after euthanasia, bronchoalveolar lavage fluid cells and lung tissue were assessed for inflammation and fibrosis.

Results: Aspiration of recombinant murine NEU3 caused inflammation and fibrosis in the lungs, while inactive NEU3 caused inflammation but not fibrosis. Mice were also treated with recombinant murine NEU3 starting 10 days after bleomycin. In male but not female mice, recombinant murine NEU3 increased inflammation and fibrosis. Inactive NEU3 did not enhance bleomycin-induced lung fibrosis.

Conclusion: These results suggest that NEU3 is sufficient to induce fibrosis in the lungs, that aspiration of NEU3 has a greater effect on male mice, and that this effect is mediated by NEU3's enzymic activity.

Keywords: Sialidase, NEU3, Glycosylation, Inflammation, Fibrosis, Lung, Macrophage, Bleomycin

Background
Fibrosing diseases, such as idiopathic pulmonary fibrosis (IPF), cardiac fibrosis, liver cirrhosis, and end-stage kidney disease, involve the progressive formation of scar tissue in internal organs that replaces the normal tissue, and are an increasing burden for healthcare systems [1–4]. IPF is a chronic and fatal disease that affects ~3 million people worldwide, with an incidence of 1 in 200 > 65 years, and is characterized by fibrosis of the lungs and if untreated has a median survival of 3–5 years after initial diagnosis [5–7]. The only FDA-approved therapeutics, Nintedanib and Pirfenidone, slow but do not reverse the progression of the disease [6, 8].

Many secreted and cell-surface mammalian proteins are glycosylated, and many of the glycosylated structures have sialic acids as the monosaccharide at the end of the polysaccharide chain [9–11]. Sialidases, which are also called neuraminidases, remove the terminal sialic acid from these glycoconjugates [12, 13]. There are four known mammalian sialidases, NEU1, NEU2, NEU3, and NEU4, and each sialidase has different subcellular localizations and substrate specificities [12–14]. Of the four sialidases, only NEU3 is primarily extracellular [14–17]. This enzyme uses two tyrosines in the active site to remove sialic acid from glycoconjugates [13, 18].

*Correspondence: dpilling@bio.tamu.edu; rgomer@tamu.edu
Department of Biology, Texas A&M University, 301 Old Main Drive, College Station, TX 77843-3474, USA
The lungs from both preclinical models of lung fibrosis and patients with IPF have increased levels of sialidase activity in the bronchoalveolar lavage fluid (BALF), increased levels of NEU3 in the BALF, and increased levels of both NEU1 and NEU3 in the lung tissue [19–23]. Mice treated with NEU1 and NEU3 inhibitors, and Neu3−/− knockout mice, show strongly attenuated inflammation and fibrosis after bleomycin challenge [22–26], suggesting that NEU3 is necessary for the full extent of bleomycin-induced inflammation and fibrosis.

In this report, we assessed whether NEU3 might be sufficient to induce fibrosis. We previously found that mice have low levels of NEU3 (~1.7 ng) in their BALF, while mice treated with bleomycin have ~15 ng of NEU3 in their BALF at day 21 [23]. We find that aspiration of 15 ng of murine NEU3 every other day for 20 days caused inflammation and fibrosis in the lungs at day 21, and that the fibrosis was not observed using a mutated and thus inactive NEU3 lacking the two key tyrosines in the active site. We also find that NEU3 potentiates bleomycin-induced inflammation and pulmonary fibrosis. These results suggest that NEU3 is sufficient to induce fibrosis.

**Methods**

**Recombinant murine NEU3 expression**

Chinese hamster ovary (CHO-K1) cells were cultured in CD4CHO medium with l-glutamine (Cat# SH30557.02, Hyclone/Cytiva, Marlborough, MA, USA). Cells (1 × 10⁵) were mixed with 2 μg of 100 μg/ml of murine NEU3 expression plasmid (MR223297; OriGene, Rockville, MD, USA) in 100 μl PBS (GE Lifesciences, Marlborough, MA, USA) and were transfected by electroporation using a 4D-Nucleofector System (Lonza, Cranbury, NJ, USA) following the manufacturer’s protocol. Before use, the plasmid was sequenced for verification as previously described [25, 27–29]. The transfected cells were kept at room temperature for 15 min for recovery, after which the CHO-K1 cells were cultured in 25 ml CD4CHO medium in a humidified incubator at 37 °C with 5% CO₂. After 24 h, 400 μg/ml of G418 (345812; Calbiochem EMD, San Diego, CA) was added to select for transfected cells. After 10 days, the cells were collected and lysed, and c-Myc–tagged recombinant murine NEU3 was purified using a Myc-Trap agarose kit (ytak-20; Chromotek, Hauppaug, NY, USA) following the manufacturer’s protocol. Recombinant protein was checked for protein concentration by OD 260/280/320 using a Take3 micro-volume plate with a SynergyMX plate reader (BioTek, Winooski, VT, USA). NEU3 is 51 kDa, and was further purified by centrifugation at 10,000 × g for 5 min at 4 °C through an Amicon Ultra 0.5 ml 100 kDa cutoff spin filter (Millipore, Billerica, MA, USA). The NEU3 was analyzed for size and purity by PAGE on, and Coomassie staining of, 4–20% Tris/glycine gels (Bio-Rad, Hercules, CA, USA), as described previously [25, 27–29]. The NEU3 was stored in 50 μl of 10% glycerol, 100 mM glycine, and 25 mM Tris–HCl, pH 7.3, at 4 °C.

**Recombinant murine inactive NEU3 variant generation**

Starting with the murine NEU3 expression plasmid MR223297, a variant mutated to change the tyrosines at positions 179 and 181 to phenylalanines was generated using a QuikChange II Site-Directed Mutagenesis Kit (#200523; Agilent, Santa Clara, CA, USA) and the primer 5’ CATCCCCGCCTTGCCTTTCTATGTCTCACGT TGG 3’, with the underscored sequences representing the point mutation sites. Other workers found that these two mutations eliminate NEU3 sialidase activity [18]. The resulting plasmid was sequenced to confirm the point mutations and absence of other mutations.

**Cell isolation and culture**

Human peripheral blood was collected from healthy volunteers who gave written consent with specific approval from the Texas A&M University human subjects review board (IRB2009-0671D). All methods were performed in accordance with the relevant guidelines and regulations. Blood collection, isolation of peripheral blood mononuclear cells (PBMC), and cell culture were done as described previously [22, 23, 25, 30]. Murine spleen cells were isolated by forcing diced spleen fragments through a 100 μm cell strainer (BD Biosciences, San Jose, CA, USA) and the ability of NEU3 to induce extracellular accumulation of IL-6 from human PBMC and murine spleen cells [23, 25], using human (BioLegend) and murine (PeproTech, Cranbury, NJ, USA) IL-6 ELISA kits following the manufacturers’ protocols.

**Mouse models of pulmonary inflammation and fibrosis.**

This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by Texas A&M University Animal Use and Care Committee (IACUC 2020-0272). All procedures were performed under 4% isoflurane in oxygen anesthesia, and all efforts were made to minimize suffering. Animals were housed with a 12-h/12-h light–dark cycle with free access to food and water, and all procedures were performed between 09:00 and noon. To induce inflammation and fibrosis, 7–8 week old 20–25 g male and female C57BL/6 mice (Jackson Laboratories, Bar Harbor, ME, USA) were given an oropharyngeal...
as described previously [22, 23, 25, 32]. Briefly, slides spots were fixed and immunochemistry was performed drying for 48 h at room temperature, some of the cell spots were incubated with antibodies diluted to 5 µg/ml in PBS containing 2% IgG-free BSA (BSA-066-152, Jackson Laboratories, West Grove, PA, USA) or biotinylated donkey F(ab′)2 anti-rabbit (711-1202, clone M1/70, BioLegend, San Diego, CA, USA) antibodies as controls. After washing six times with PBS for 5 min each, the slides were incubated at room temperature for 30 min with 1 µg/ml biotinylated donkey anti-rat (NBP1-75379, Novus) or biotinylated donkey F(ab′)2 anti-rabbit (711-066-152, Jackson Laboratories, West Grove, PA, USA) secondary antibodies. After washing, the biotinylated antibodies were detected with a 1/500 dilution of ExtrA-vidin alkaline phosphatase (SA-5100-1, Vector Laboratories, Newark, CA, USA). Staining was developed with the Vector Red Alkaline Phosphatase Kit (SK-5100, Vector), following the manufacturers’ protocols. Slides were then counterstained with Gill’s hematoxylin (Sigma-Aldrich).

Using a 40 × objective, at least 150 cells from each stained BALF spot were examined and the percent positive cells was recorded.

**Lung histology**

After collecting BALF, the lungs from the mice were harvested and inflated with Surgipath frozen section compound (#3801480, Leica, Buffalo Grove, IL, USA), frozen on dry ice, and stored at − 80 °C. 10 µm cryosections of lung were placed on Superfrost Plus glass slides (VWR) and were air dried for 48 h. Immunohistochemistry was done as previously described [22, 23, 25, 32] and as detailed above using anti-CD3, anti-CD11b, anti-CD11c, anti-CD45, anti-Ly6g, or anti-Mac2 (clone M3/38; BioLegend) antibodies with isotype-matched irrelevant rat and rabbit as controls. Positively stained cells were counted from randomly selected fields, and presented as the number of positive cells per mm², as described previously [22, 23, 25, 32]. Lung sections were also stained with Sirius red to detect collagen and analyzed as previously described [23, 25, 34, 35]. Briefly, images were converted to RGB stacks using Image J, and then the green channel (which shows the red staining) was analyzed. Intensity of staining was determined using the threshold tool, which was kept the same for analyzing each set of images. The area stained as a percentage of the total area of the lung tissue was then determined using Image J. Other investigators and ourselves have shown that histological analysis of fibrosis and collagen content by sirius red staining, correlates well with collagen content as measured by antibody staining and hyproxyproline and sirius red (Sircol) assays [23, 25, 34–38]. Lung sections were also stained using rabbit polyclonal anti-collagen VI antibodies (NB120-6588, Novus Biologicals), as described previously [34, 39]. Lung sections stained with picrosirius red were assessed histologically for fibrosis, using the Ashcroft system, as described previously [38, 40].

**Statistical analysis**

Statistical analysis was performed using Prism Version 7.05 (GraphPad Software, La Jolla, CA, USA). Statistical significance between two groups was determined by t test, or between multiple groups using analysis of variance (ANOVA) with both Bonferroni’s and Sidak’s post-tests, and significance was defined as p < 0.05.

**Results**

**Recombinant murine NEU3, but not mutated NEU3, has NEU3 activity**

We previously observed that the BALF from fibrotic lungs, and fibrotic lesions from human and mouse lungs, have elevated levels of NEU3, that NEU3 inhibitors attenuate bleomycin-induced pulmonary fibrosis, and that
Neu3−/− knockout mice are resistant to bleomycin-induced inflammation and fibrosis [22, 23, 25]. To further elucidate the contribution of NEU3 to fibrosis, we generated recombinant murine NEU3 and a mutated recombinant murine NEU3 protein with two point mutations in the active site. NEU3 and mutated NEU3 were 51 kDa as assessed by PAGE and Coomassie staining (Fig. 1A). Recombinant human NEU3 induces the accumulation of IL-6 from human peripheral blood mononuclear cells (PBMC), and this is blocked by NEU3 inhibitors [22, 23, 25], indicating that the effect on IL-6 is dependent on NEU3 activity. The recombinant murine NEU3, but not the mutated NEU3, upregulated extracellular accumulation of IL-6 in both human and murine cells (Fig. 1B, C), indicating that the recombinant murine NEU3 has NEU3 activity and that the mutated NEU3 does not and is thus inactive.

Aspiration of NEU3 or inactive NEU3 induces inflammation
To determine if elevated levels of NEU3 protein in the lung, without any other exogenous insult, could induce inflammation and/or fibrosis, mice received 15 ng of either
Fig. 3  Increase in immune cells in lungs post-BAL of NEU3 treated mice. Cryosections of male and female mouse lungs were stained for A CD3, B CD11b, C CD11c, D CD45, E Mac2 and F Ly6g and counts were converted to the number of positive cells per mm². Values are mean ± SEM, n = 6 mice (3 male and 3 female). *p < 0.05; **p < 0.01 (one-way ANOVA, Bonferroni’s or Sidak’s test)
recombinant (rec) murine NEU3 or rec murine inactive NEU3 every 48 h by oropharyngeal aspiration. This dose of NEU3 corresponds to the total amount of native mouse NEU3 in the BALF of mice at day 21 after bleomycin [23]. There was no discernable effect of rec NEU3 on the appearance or behavior of the mice, aspiration did not significantly affect body weight, or white fat, liver, kidney, spleen, heart, or brown fat weights as a percent of total body weight (Additional file 1: Fig. S1A–C). Compared to naive controls, rec NEU3 aspiration increased BALF cell counts and B BALF AL CD11b, CD11c and CD45 cell counts in male and female mice (Fig. 2). Compared to rec NEU3-treated mice, rec inactive NEU3-treated mice had lower BALF cell counts (Fig. 2A), and this trend was observed in both male and female mice (Additional file 2: Fig. S2A). Compared to NEU3 aspiration, aspiration of inactive NEU3 caused a smaller increase in CD45 cells in the BALF (Fig. 2B), which was also due to the effect on female but not male mice (Additional file 2: Fig. S2B, C). There were no significant differences in BALF protein levels between naïve mice (1.2 ±0.2 mg/ml; mean ±SEM, n=6), NEU3 (1.8 ±0.4 mg/ml; mean ±SEM, n=6) and inactive NEU3 (1.4 ±0.9 mg/ml; mean ±SEM, n=6) treated mice.

After removing BALF, lung sections were stained to detect immune cells that were not removed by lavage. Compared to naive mice, NEU3 increased the number of CD11b, CD11c, CD45, Mac2, and Ly6g positive cells in the lung tissue (Fig. 3; Additional file 3: Fig. S3). In male mice, compared to naive mice, NEU3 increased the number of CD3, CD11b, CD45, and Mac2 positive cells in the lungs (Additional file 4: Fig. S4A–F). In female mice, NEU3 decreased CD3 positive cells and increased Mac2 and Ly6g positive cells (Additional file 4: Fig. S4E, F). Compared to NEU3 aspiration, aspiration of inactive NEU3 did not significantly affect counts of cells expressing any of the 6 markers (Fig. 3; Additional file 4: Fig S4). Together, the data indicate that aspiration of either form of NEU3 induces inflammation in the lungs of mice.

**Aspiration of NEU3 but not inactive NEU3 induces fibrosis**

Lung sections were also stained with picrosirius red to detect total collagen (Fig. 4A–F). In male and female mice, aspiration of NEU3 but not inactive NEU3 caused an increase in picrosirius red staining (Fig. 4G–I). Lung sections were also stained with anti-collagen-VI antibodies (Fig. 4J–O). In male but not female mice, aspiration of NEU3 but not inactive NEU3 caused an increase in collagen VI staining (Fig. 4J, K, L). These data suggest that NEU3 induces fibrosis, that the effect is dependent on NEU3 activity, and that for unknown reasons, the fibrosis in female mice is not accompanied by an increase in collagen VI staining.

**Following bleomycin, aspiration of NEU3 but not inactive NEU3 increases inflammation in male mice**

Bleomycin aspiration is a standard way to increase inflammation and fibrosis in the lungs of mice [41, 42], and we found that this also increases levels of NEU3 in the lungs [22, 23, 25]. To determine if further increasing levels of NEU3 in the lungs would alter inflammation and fibrosis after aspiration of bleomycin, male and female mice were treated with saline or bleomycin at day 0, and then from days 10 to 20 received 15 ng of either NEU3, inactive NEU3, or saline control every 2 days by oropharyngeal aspiration. As observed previously [43, 44], male mice that received bleomycin have a drop in body weight between days 3 and 10, but there was no significant weight loss in the female mice (Fig. 5A, B). Aspiration of NEU3 or inactive NEU3 did not significantly alter the weights of the mice (Fig. 5A, B). As previously observed, compared to saline controls, bleomycin instillation led to an increase in the number of cells recovered from the BALF in both male and female mice at day 21 (Fig. 5C, D). In the lungs of male mice that received bleomycin, NEU3 aspiration had significantly higher BALF cell counts compared to saline or inactive NEU3 treated mice (Fig. 5C). In female mice that received either saline or bleomycin, NEU3 aspiration did not significantly alter BALF cell counts (Fig. 5D). In bleomycin-treated male but not female mice, aspiration of NEU3 but not inactive NEU3 increased the number of CD11c and CD45 positive cells in the BALF at day 21 (Fig. 6A).

In the lung tissue of bleomycin-treated mice after BAL, NEU3 aspiration, but not aspiration of inactive NEU3, increased the numbers of CD11c and CD45 positive cells (Fig. 7), which was due to the effect on male but not

(See figure on next page.)

**Fig. 4** NEU3 but not inactive NEU3 induces fibrosis. Sections of lung tissue from naïve mice and mice treated with NEU3 or inactive NEU3 were stained with A–I picrosirius red to show collagen content, and J–O anti-collagen VI antibodies. A Naive (control), B NEU3 (WT), and C inactive (In) NEU3 treated male mice, and D Naive (control), E NEU3 (WT), and F inactive (In) NEU3 treated female mice stained with picrosirius red. All images are representative of three mice per group. Bar is 0.1 mm. G–I Picrosirius red quantification of G combined male and female mice, H male and I female mice. J NEU3, and K inactive NEU3 treated male mice, and L NEU3, and M inactive NEU3 treated female mice stained with anti-collagen VI antibodies. N–O Collagen VI quantification of N male and O female mice. Values are mean ±SEM, n=6 combined mice (3 male and 3 female), or n = 3 for male and female mice analyzed separately. *p < 0.05, **p < 0.01 (one-way ANOVA, Bonferroni’s or Sidak’s test)
Fig. 4 (See legend on previous page.)
female mice (Additional file 5: Fig. S5A, B). Together, the results suggest that in male but not female mice, increasing levels of NEU3 starting at day 10 after bleomycin causes a further increase in inflammation.

Aspiration of NEU3 but not inactive NEU3 for 10 days increases fibrosis

Lung sections were also stained with picrosirius red to detect total collagen (Fig. 8A–L). In saline treated male and female mice, aspiration of NEU3, but not inactive NEU3, from day 10–20 increased picrosirius red staining (Fig. 8M and Additional file 6: Fig S6A, B). In bleomycin treated mice, NEU3 aspiration increased picrosirius red staining (Fig. 8M), which was statistically significant in male but not female mice (Additional file 6: Fig. S6C, D). Lung fibrosis was also assessed by histology (Fig. 8U). In saline treated male and female mice, aspiration of NEU3 but not inactive NEU3 increased fibrosis (Fig. 8U). In bleomycin treated mice, compared to inactive NEU3, NEU3 aspiration increased fibrosis (Fig. 8U) in both male and female mice (Additional file 6: Fig. S6A, B). These data suggest that increasing NEU3 can increase fibrosis, and that this effect requires NEU3 activity.
Discussion

In this report, we observed that the murine sialidase NEU3, but not enzyme inactive murine NEU3, can induce IL-6 production from human and murine cells as observed previously for human NEU3 [23, 45]. We also observed that NEU3 treatment increased the number of immune cells in the BALF and lung tissue both alone and after instillation of bleomycin, compared to naïve and saline treated mice, respectively. In the absence of any other exogenous insult, aspiration of inactive NEU3 every other day from day 0 to day 20, but not from day 10 to day 20, increased the number of cells in the BALF compared to naïve mice. This suggests that 11 but not 6 aspirations of inactive NEU3 can cause an increase in the number of cells in the BALF. In both experiments, the response to inactive NEU3 was less than that of enzyme active NEU3. NEU3, but not inactive NEU3, also increased picrosirius red staining in male and female mice, and collagen VI staining in male but not female mice. We also observed that in male mice, NEU3 augmented the number of cells in the BALF following bleomycin, and that inactive NEU3 did not augment the inflammatory response compared to active NEU3. NEU3 treatment also upregulated the fibrotic response in both male and female mice when given alone, but only NEU3, and not inactive NEU3, augmented the fibrotic response after bleomycin challenge. This suggests that elevated levels of NEU3 found in inflammatory and fibrotic tissues are not only a marker of fibrotic disease, but actively contribute to the disease process.

The inhalation of proteins into the lungs might be sufficient to induce an inflammatory or fibrotic response. However, we have previously shown that the aspiration of the neutrophil chemorepellent protein DPP4, when given without bleomycin challenge, had no significant effect on number of lymphocytes or macrophages in either the BALF, or in lung tissue [46]. Other investigators have also shown that aspiration of serum amyloid P (SAP), an anti-fibrotic protein, in the absence of a fibrotic stimulus, had no effect on BALF cell numbers, apoptosis, or collagen content in mouse lungs [47]. In addition, inhaled proteins are used to treat disease, such as recombinant deoxyribonuclease I for cystic fibrosis [48]. These data suggest that inhalation of proteins that are not inherently inflammatory or damaging to the lung, in the absence of any other insult, are unlikely to generate inflammation and fibrosis, and that the effect of inhaled NEU3 on inflammation and fibrosis, is due to the effect of active NEU3 enzyme.

Elevated NEU3 levels are found during inflammation and fibrosis in many organ systems, Neu3−/− knock-out mice show an attenuated inflammatory and fibrotic response, and NEU3 inhibitors reduce these responses...
in wild type mice [19–26, 49–52]. We observed that the instillation of exogenous active NEU3, but not the inactive NEU3, augmented bleomycin-induced lung inflammation in male mice, and fibrosis in male and female mice. This suggests that following a lung insult, such as bleomycin, the observed effects of NEU3 on inflammation and fibrosis could be in part due to the enzymatic activity of NEU3 rather than the presence of the NEU3 protein itself. Other investigators, and this report, observed that compared to male mice, female mice have a reduced fibrotic response to bleomycin ([43, 44]; Fig. 8). We observed in this report that female mice have a reduced fibrotic response to aspirated NEU3 following bleomycin. This suggests that compared to male mice, female mice may have a reduced sensitivity to NEU3. Despite these sex differences, our results indicate that NEU3 potentiates pulmonary fibrosis.

**Conclusions**

We demonstrated for the first time that physiologically relevant levels of exogenous NEU3 when inhaled into the lung of can induce fibrosis in the absence of any other insult. We also observed that compared to male mice, female mice may have a reduced sensitivity to NEU3. Our findings suggest that elevated levels of NEU3 in the lung are sufficient to induce lung inflammation and fibrosis.
Additional file 1: Fig S1. Aspiration of recombinant murine NEU3 or inactive NEU3 had no significant effect on body weight or organ weights. Percent change in body weight of A) male and B) female naïve mice, or mice after aspiration of recombinant (rec) murine NEU3 or inactive NEU3 for every 48 h for 20 days. C) Weights of white fat, liver, kidneys, spleen, heart, and brown fat as percentage of total bodyweight at day 21. Values are mean ± SEM, n = 6 (3 male and 3 female mice). There were no significant changes as determined by t test or one-way ANOVA, Bonferroni’s or Sidak’s test.

Additional file 2: Fig S2. NEU3 treated male and female mice have increased numbers of bronchoalveolar lavage (BAL) cells. A) The total number of cells in mouse BAL after the indicated treatment from male and female mice. Values are mean ± SEM, n = 3 male and 3 female mice per group. B-C) BAL cell spots at day 21 were stained for the markers CD3, CD11b, CD11c, CD45, and Ly6g, and the percent of cells stained was determined, and the percentage was multiplied by the total number of BAL cells for that mouse to obtain the total number of BAL cells staining for the marker. Values are mean ± SEM, n = 3 male and 3 female mice. *p < 0.05; **p < 0.01, ***p < 0.001 (one-way ANOVA, Bonferroni’s or Sidak’s test).

Additional file 3: Fig S3. Increase in CD45 positive immune cells in lungs post-BAL of NEU3 treated male and female mice. Cytoresections of male and female mouse lungs were stained for CD45. A and B) Naïve (control), C and D) NEU3 (WT), and E and F) inactive NEU3 treated male A, C, E, and female B, D, and F) mice. G) Isotype irrelevant control antibody. All images are representative of three mice per group. Bar is 0.1 mm.

Additional file 4: Fig S4. Increase in immune cells in lungs post-BAL of NEU3 treated male and female mice. Cytoresections of male and female mouse lungs were stained for A) CD3, B) CD11b, C) CD11c, D) CD45, E) Mac2 and F) Ly6g and counts were converted to the number of positive cells per mm². Values are mean ± SEM, n = 3 male and 3 female mice. *p < 0.05; **p < 0.01 (one-way ANOVA, Bonferroni’s or Sidak’s test).

Additional file 5: Fig S5. NEU3, but not inactive NEU3, treated male and female mice have increased numbers of inflammatory cells in lung tissue following bleomycin aspiration. Cytoresections of A) male and B) female mouse lungs were stained for CD3, CD11b, CD11c, CD45, Mac2, and Ly6g, and counts were converted to the number of positive cells per mm². Values are mean ± SEM, n = 3 male and 3 female mice. *p < 0.05; (one-way ANOVA, Bonferroni’s or Sidak’s test).

Additional file 6: Fig S6. Enhanced fibrotic response in NEU3 treated male and female mice following bleomycin. Sections of lung tissue from male and female mice treated with saline (S) or bleomycin (B) aspiration at day 0, and NEU3 (WT) or inactive (IN) NEU3 treatment from days 10 to 20. Quantification of A-B) picrosirius red, C-D) anti-collagen VI antibody staining, and E-F) histological assessment of fibrosis. Values are mean ± SEM, n = 3 male and n = 3 female mice. *p < 0.05; **p < 0.01 ***p < 0.001 (one-way ANOVA, Bonferroni’s or Sidak’s test).

Acknowledgements

Author contributions

We thank the LARR (Laboratory Animal Resources and Research) staff at Texas A&M University for animal care.

Funding

This work was supported by National Institutes of Health National Heart, Lung, and Blood Institute [Grant R01 HL132919]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Declarations

Ethics approval and consent to participate

Human peripheral blood was collected from healthy volunteers who gave written consent with specific approval from the Texas A&M University human subjects review board (IRB2009-0671D). Animal experiments were carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by Texas A&M University Animal Use and Care Committee (IACUC 2020-0272).

Consent for publication

Not applicable.

Competing interests

RHG is a scientific founder of Prosia Therapies, an early stage company developing NEU3 inhibitors as therapeutics for pulmonary fibrosis. Texas A&M University has published patent applications on the use of sialidase inhibitors (United States Patent Application 20190201485) to regulate fibrosis. DP and RHG are inventors on pending patent applications for the use of sialidase inhibitors as anti-inflammatory and/or anti-obesity compounds.

Availability of data and materials

The data that support the findings of this study are available from the corresponding authors upon reasonable request.

Received: 30 March 2022 Accepted: 15 August 2022
Published online: 23 August 2022

References

1. Barnes PJ, Anderson GP, Fagerström M, Belvisi MG. Chronic lung diseases: prospects for regeneration and repair. Eur Respir Rev. 2021;30: 200013.
2. Raimundo K, Chang E, Broder MS, Alexander K, Zazzali J, Swigris J. Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study. BMC Pulm Med. 2016;16:2.
3. Spalla G, Kulkarni T, Antin-Ozerkis D, Thaninkal VJ, Richeldi L. Update in pulmonary fibrosis 2018. Am J Respir Crit Care Med. 2019;200:292–300.
4. Schattenberg JM, Lazarus JV, Newsome PN, Serfky L, Aghemo A, Augustin S, Tsochatzis E, de Ledinghen V, Bugiansi E, Romero-Gomez M, et al. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (nash) in five european countries in 2018: a cost-of-illness analysis. Liver Int. 2021.
5. Raghu G, Rochwerger B, Zhang Y, Garcia CA, Azuma A, Behr J, Brozek JL, Collard HR, Cunningham W, Homma S, et al. An Official ATS/ERS/JRS/ ALAT Clinical Practice Guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med. 2015;192:e3–19.
6. Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med. 2018;378:1811–23.
7. Cotton V, Spagnolo P, Bonnanda P, Nolín M, Dallon F, Kirchgässler K-U, Kamath TV, Van Ganse E, Belhassen M. Mortality and respiratory-related hospitalizations in idiopathic pulmonary fibrosis not treated with antifibrotics. Front Med. 2021; 8.
8. Raghu G, Selman M. Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions. Am J Respir Crit Care Med. 2015;191:252–4.
9. Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol. 2013;13:176–89.
10. Freire-de-Lima L, Oliveira IA, Neves JL, Penha LL, Alisson-Silva F, Dias WB, Todeschini AR. Sialic acid: a sweet swing between mammalian host and Trypanosoma cruzi. Front Immunol. 2012;3:136.

11. Varki A, Gagneux P. Multifarious roles of sialic acids in immunity. Ann N Y Acad Sci. 2012;1253:16–36.

12. Monti E, Miyagi T. Structure and function of mammalian sialidases. Top Curr Chem. 2015;366:183–208.

13. Smutova V, Albohy A, Pan X, Korchagina E, Miyagi T, Bovin N, Kawo CW, Psheshetsky AV. Structural basis for substrate specificity of mammalian neuraminidases. PLoS ONE. 2014;4:9.e106320.

14. Miyagi T, Yamaguchi K. Mammalian sialidases: Physiological and pathobiological roles in cellular functions. Glycobiology. 2012;22:880–96.

15. Zanchetti G, Colombo P, Manzoni M, Anastasia L, Caimi L, Borsani G, Venerando B, Tettamanti G, Preti A, Monti E, Bresciani R. Sialidase NEU3 is a peripheral membrane protein localized on the cell surface and in endosomal structures. Biochem J. 2007;408:211–9.

16. Cirillo F, Ghiroldi A, Fania C, Piccoli M, Torretta E, Tettamanti G, Gelfi C, Anastasia L, NEU3 sialidase protein interactors in the plasma membrane and in the endosomes. J Biol Chem. 2016;291:10615–24.

17. Rodriguez-Walker M, Daniotti JL. Human sialidase Neu3 is S-acetylated and behaves like an integral membrane protein. Sci Rep. 2017;7:4167.

18. Albohy A, Li MD, Zheng RB, Zou C, Cairo CW. Insight into substrate recognition and catalysis by the human neuraminidase 3 (NEU3) through molecular modeling and site-directed mutagenesis. Glycobiology. 2010;20:1127–38.

19. Lambré CR, Pitlyte Y, Le Maho S, Greflard A, De Crémoux H, Bignon J. Sialidase activity and antibodies to sialidase-treated autologous erythrocytes in bronchoalveolar lavages from patients with idiopathic pulmonary fibrosis or sarcoidosis. Clin Exp Immunol. 1988;73:230–9.

20. Lillehoj EP, Hyun SW, Feng C, Zhang L, Liu A, Guang W, Nguyen C, Sun W, Luzina IG, Webb TJ, et al. Human airway epithelia express catalytically active NEU3 sialidase. Am J Physiol Lung Cell Mol Physiol. 2014;306:L876-886.

21. Luzina IG, Lockatell V, Hyun SW, Kopach P, Kang PH, Noor Z, Liu A, Lillehoj EP, Lee C, Miranda-Ribera A, et al. Elevated expression of NEU1 sialidase in idiopathic pulmonary fibrosis provokes pulmonary collagen deposition, lymphocytosis, and fibrosis. Am J Physiol Lung Cell Mol Physiol. 2016;310:1940-954.

22. Karhadkar TR, Pilling D, Cox N, Gomer RH. Sialidase inhibitors attenuate pulmonary fibrosis in a mouse model. Sci Rep. 2017;7:15069.

23. Karhadkar TR, Chen W, Gomer RH. Attenuated pulmonary fibrosis in sialidase-3 knockout (Neu3(−/−)) mice. Am J Physiol Lung Cell Mol Physiol. 2018;315:L165-l179.

24. Hyun SW, Liu A, Liu Z, Cross AS, Verceles AC, Maghes S, Kommaqalla Y, Kona C, Ando H, Luzina IG, et al. The NEU1-selective sialidase inhibitor, C9-butyrl-amide-DANA, blocks sialidase activity and NEU1-mediated bioactivities in human lungs in vitro and murine lung in vivo. Glycobiology. 2016;26:834–49.

25. Karhadkar TR, Meek TD, Gomer RH. Inhibiting sialidase-induced TGF-β1 activation attenuates pulmonary fibrosis in mice. J Pharmacol Exp Ther. 2020.

26. Luzina IG, Lillehoj EP, Lockatell V, Hyun SW, Lugkey KN, Iamamura A, Ishida H, Cairo CW, Atamas SP, Goldblum SE. Therapeutic effect of neuraminidase-1-selective inhibition in mouse models of bleomycin-induced pulmonary inflammation and fibrosis. J Pharmacol Exp Ther. 2021;376:136.

27. Crawford JR, Pilling D, Gomer RH. FcγRI mediates serum amyloid P inhibitory function and IL-6 production in murine fibrocytes. J Immunol. 2010;184:4035–44.

28. Crawford JR, Pilling D, Gomer RH. Improved serum-free culture conditions for sialic-acid-derived murine fibrocytes. J Immunol Methods. 2010;363:9–20.

29. Pilling D, Gomer RH. Persistent lung inflammation and fibrosis in serum amyloid P component (Apac)−/− knockout mice. PLoS ONE. 2014;9:e93730.

30. Pilling D, Zheng Z, Vakil V, Gomer RH. Fibroblasts secrete Silt2 to inhibit fibrocyte differentiation and fibrosis. Proc Natl Acad Sci USA. 2014;111:18291–6.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.